Evaluation of the effect of liposomal miR-143 on cell viability and anti-apoptotic gene expression of Bcl-2 in human osteosarcoma cells for the treatment of metastatic cancers
Introdution: The present study was conducted to evaluate the effect of miR-143 on the expression of Bcl2 gene at the level of mRNA, cell cytotoxicity in the SaOs-2 cell line (Osteosarcoma) and Hum 63 (Human primary bone cells). Methods: In this experimental study, miR-143 was introduced into the SaO...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | fas |
| Published: |
Shahid Sadoughi University of Medical Sciences
2018-10-01
|
| Series: | Majallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Shahīd Ṣadūqī Yazd |
| Subjects: | |
| Online Access: | http://jssu.ssu.ac.ir/browse.php?a_code=A-10-303-5&slc_lang=en&sid=1 |
| Summary: | Introdution: The present study was conducted to evaluate the effect of miR-143 on the expression of Bcl2 gene at the level of mRNA, cell cytotoxicity in the SaOs-2 cell line (Osteosarcoma) and Hum 63 (Human primary bone cells).
Methods: In this experimental study, miR-143 was introduced into the SaOs-2 and Hum 63 cell by the lipofectam 2000 system. Then, the effects of miR-143 on cytotoxicity (72 hours) and expression of Bcl2 gene were measured by the MTT tests and Real Time Pcr protocols, respectively.
Results: The results showed that the lipofectamine 2000 system had no toxicity in both Hum63 and SaOs2 cell lines by itself. SaOs2 cancer cells were more susceptible to miR-143 and Lipo / miR-143 compared to Hum63 cells. The highest reduction in SaOs2 cells was observed after the treatment with Lipo / miR-143 (p <0.05). Furthermore, according to the results, transfection of miR-143 by lipofectamine 2000 into the cell, compared to cell-treated alone by miR-143, significantly reduced Bcl2 expression (p <0.05).
Conclusion: The lipoprotein 2000 system can be effective in absorbing miR-143 into the cells. By targeting various cellular pathways, including the expression level of the Bcl2 gene, miR-143 can be effective in the treatment of bone cancer (Osteosarcoma). |
|---|---|
| ISSN: | 2228-5741 2228-5733 |